# Andrew Tutt

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andrew-tutt/

## Facts

| Field | Value |
| --- | --- |
| Citations | 87,385 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 102 |
| i10-index | 222 |
| Last Known Institution | Institute of Cancer Research |
| OpenAlex ID | https://openalex.org/A5087121536 |
| ORCID iD | https://orcid.org/0000-0001-8715-2901 |
| Works | 769 |

## Researcher papers

Showing 12 of 13.

- [Signatures of mutational processes in human cancer](https://scholariq.org/papers/signatures-of-mutational-processes-in-human-cancer/)
- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers](https://scholariq.org/papers/inhibition-of-poly-adp-ribose-polymerase-in-tumors-from-i-brca-i-mutation/)
- [Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial](https://scholariq.org/papers/oral-poly-adp-ribose-polymerase-inhibitor-olaparib-in-patients-with-brca1-or/)
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [The landscape of cancer genes and mutational processes in breast cancer](https://scholariq.org/papers/the-landscape-of-cancer-genes-and-mutational-processes-in-breast-cancer/)
- [Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer](https://scholariq.org/papers/adjuvant-olaparib-for-patients-with-i-brca1-i-or-i-brca2-i-mutated-breast-cancer/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial](https://scholariq.org/papers/carboplatin-in-brca1-2-mutated-and-triple-negative-breast-cancer-brcaness/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Genomic Evolution of Breast Cancer Metastasis and Relapse](https://scholariq.org/papers/genomic-evolution-of-breast-cancer-metastasis-and-relapse/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

## Researcher university

- [Institute of Cancer Research](https://scholariq.org/institutions/institute-of-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.